On CNBC's "Power Lunch," a Wall Street analyst stated that Amgen's recently approved migraine drug, Aimovig, could become a $2 billion business in the next five years. That revenue would equate to a 10 percent increase to Amgen's revenue as the drug provides a huge unmet need for adults who deal with migraines. ...
Amgen's new migraine drug will cost 30 percent less than Wall Street expected via @statnews $AMGN https://t.co/mw5s8bXdjN pic.twitter.com/hdnOZ52cMg— medtech[y] (@medtechy) May 18, 2018
Allergan is taking advantage of the popularity of CoolSculpting, the procedure they acquired from ZELTIQ, by launching a DTC marketing campaign. CoolSculpting revenue has continued strong growth in recent quarters and helped offset declines in other Allergan product categories....
Novartis sacrifices its top attorney in an attempt to quell clamor over $1.2M in Cohen payments — while ex-CEO Jimenez struggles to explain via @endpts $NVS https://t.co/yu5bz4BFZf pic.twitter.com/Y5l6GaZow4— medtech[y] (@medtechy) May 17, 2018
FDA approves first nonopioid drug to ease withdrawal symptoms https://t.co/E1AbpA5bWc pic.twitter.com/YfvGyu8gii— medtech[y] (@medtechy) May 17, 2018
A big drugmaker is backing away from a plan to triple the price of a lifesaving cancer drug after facing a public backlash $ABBV $JNJ https://t.co/AxQFUPM9GJ pic.twitter.com/yx2gtszvAV— medtech[y] (@medtechy) May 16, 2018
Whisky and Apologies Aided Takeda's $62 Billion Shire Gamble via @BloombergDeals $TKPYY | https://t.co/9jKFGElPup pic.twitter.com/jzuN02QshC— medtech[y] (@medtechy) May 11, 2018
Never in my dreams did I think I would be writing a story that tied in a porn actress, the president of the US, a Russian oligarch and Novartis payments. https://t.co/tp2ib6UFbg— John Carroll (@JohnCendpts) May 9, 2018
Valeant to become Bausch Health Companies in rebrand set for July https://t.co/Zly9dhFDF4— FiercePharma (@FiercePharma) May 8, 2018
Takeda Buys Shire For $62 Billion Creating Pharma Giant https://t.co/JUZgl0ACRZ— zerohedge (@zerohedge) May 8, 2018